Role of Nanocarriers (Liposomes, SLNPs, Niosomes and Dendrimers) in Reproductive Health: An Emerging Paradigm

The revolution of nanotechnology in medical sciences and in drug delivery system provided targeted and controlled therapeutic interventions with maximum efficacy. Of these advancements, nanocarriers including liposomes, niosomes, SLNPs and dendrimers are of great interest in the field of reproductive healthcare. These nanomedicines improve bioavailability, decrease toxicity, and achieve more efficient organ targeting compared with clinical medication. The Polycystic Ovary Syndrome (PCOS) is one of the reproductive disorders that involve both human and animal reproductive health. PCOS endometriosis, infertility, and hormone-related imbalances. Their biocompatibility and tunable structure, liposomes and niosomes have been widely studied as vehicles for hormones and antioxidants. SLNPs provide the advantages of stability and controlled release, and dendrimers, well-defined architecture and surface modifiability, are good for encapsulation of hydrophobic drugs and for targeted therapy. Altogether, these nanocarrier platforms serve as the hopeful new era and provide a path toward more specific and personalized reproductive health care.